Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives
A Rizzo, AD Ricci, S Tavolari… - Cancer genomics & …, 2020 - cgp.iiarjournals.org
Peripheral blood of cancer patients “physiologically” presents cells and cellular components
deriving from primary or metastatic sites, including circulating tumor cells (CTCs), circulating …
deriving from primary or metastatic sites, including circulating tumor cells (CTCs), circulating …
Second-line therapies in advanced biliary tract cancers
Biliary tract cancers constitute approximately 3% of gastrointestinal malignancies with poor
prognosis. Surgical therapy is the main form of treatment in localised disease; however, for …
prognosis. Surgical therapy is the main form of treatment in localised disease; however, for …
Phase I study of chimeric antigen receptor–modified T cells in patients with EGFR-positive advanced biliary tract cancers
Y Guo, K Feng, Y Liu, Z Wu, H Dai, Q Yang… - Clinical Cancer …, 2018 - AACR
Purpose: This study is an expanded and parallel clinical trial of EGFR-specific chimeric
antigen receptor–engineered autologous T (CART) cell immunotherapy (NCT01869166) to …
antigen receptor–engineered autologous T (CART) cell immunotherapy (NCT01869166) to …
Cholangiocarcinoma
M Squadroni, L Tondulli, G Gatta, S Mosconi… - Critical reviews in …, 2017 - Elsevier
Biliary tract cancer accounts for< 1% of all cancers and affects chiefly an elderly population,
with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and …
with predominance in men. We distinguish cholangiocarcinoma (intrahepatic, hilar and …
Medical treatment for cholangiocarcinoma
Most of the patients with cholangiocarcinoma (CCA) present with advanced (inoperable or
metastatic) disease, and relapse rates are high in those undergoing potentially curative …
metastatic) disease, and relapse rates are high in those undergoing potentially curative …
Italian clinical practice guidelines on cholangiocarcinoma–Part II: treatment
Currently, the only curative treatment for cholangiocarcinoma (CCA) is surgical resection,
though this treatment is possible in less than 40% of patients. However, recent …
though this treatment is possible in less than 40% of patients. However, recent …
Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des …
B Brieau, L Dahan, Y De Rycke, T Boussaha… - Cancer, 2015 - Wiley Online Library
BACKGROUND Few data are available on second‐line chemotherapy (CT2) for advanced
biliary tract cancer (ABTC). The aim of this multicenter study was to describe the CT2 …
biliary tract cancer (ABTC). The aim of this multicenter study was to describe the CT2 …
[HTML][HTML] Precision medicine in cholangiocarcinoma
A Pellino, F Loupakis, M Cadamuro… - Translational …, 2018 - ncbi.nlm.nih.gov
Cholangiocarcinoma is one of the epithelial cancers with the poorest prognosis and the
narrowest therapeutic choice in humans. Compared with other cancer types …
narrowest therapeutic choice in humans. Compared with other cancer types …
[HTML][HTML] Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
Background Biliary tract cancer is an uncommon cancer with a poor outcome. We
assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 …
assembled data from the National Cancer Research Institute (UK) ABC-02 study and 10 …
[HTML][HTML] Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …